Literature DB >> 31357121

Stress, craving and mood as predictors of early dropout from opioid agonist therapy.

Leigh V Panlilio1, Samuel W Stull1, William J Kowalczyk1, Karran A Phillips1, Jennifer R Schroeder2, Jeremiah W Bertz1, Massoud Vahabzadeh1, Jia-Ling Lin1, Mustapha Mezghanni1, Edward V Nunes3, David H Epstein1, Kenzie L Preston4.   

Abstract

BACKGROUND: Treatment with opioid agonists is effective for opioid use disorder, but early discontinuation of treatment is a major obstacle to success. Intensive longitudinal methods - which take many repeated measurements over time, usually in the field- have provided unique insight into the effects of stress, mood and craving on drug use while people are being treated; these methods might also be useful for studying the processes that lead people to drop out of treatment.
METHODS: Ecological momentary assessment (EMA) was conducted for up to 17 weeks by obtaining multiple electronic diary entries per day from 238 participants being treated with methadone or buprenorphine-naloxone. Survival analysis was used to study two outcomes: dropping out of treatment and noncompliance with EMA self-report requirements. Self-reports of stress, craving, and mood were used as time-varying predictors. Demographic and psychosocial variables measured with the Addiction Severity Index at the start of treatment were used as time-invariant predictors.
RESULTS: Dropping out of treatment was more likely in participants with more reported hassles (a measure of stress), higher levels of cocaine craving, lower levels of positive mood, a recent history of emotional abuse, a recent history of being bothered frequently by psychological problems, and with buprenorphine rather than methadone as their medication. In contrast, study noncompliance was not significantly associated with any of the variables analyzed.
CONCLUSIONS: Assessment of stress, craving and mood during treatment might identify people who are at greater risk of dropping out, and therapeutic interventions targeting these processes might increase retention. Published by Elsevier B.V.

Entities:  

Keywords:  Buprenorphine; Dropout; Ecological momentary assessment; Methadone; Noncompliance; Opioid use disorder

Mesh:

Substances:

Year:  2019        PMID: 31357121      PMCID: PMC6707374          DOI: 10.1016/j.drugalcdep.2019.05.026

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  59 in total

Review 1.  Ecological momentary assessment in addiction.

Authors:  M Lukasiewicz; M Fareng; A Benyamina; L Blecha; M Reynaud; B Falissard
Journal:  Expert Rev Neurother       Date:  2007-08       Impact factor: 4.618

2.  When do we need competing risks methods for survival analysis in nephrology?

Authors:  Marlies Noordzij; Karen Leffondré; Karlijn J van Stralen; Carmine Zoccali; Friedo W Dekker; Kitty J Jager
Journal:  Nephrol Dial Transplant       Date:  2013-08-24       Impact factor: 5.992

Review 3.  Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.

Authors:  Richard P Mattick; Courtney Breen; Jo Kimber; Marina Davoli
Journal:  Cochrane Database Syst Rev       Date:  2014-02-06

4.  Clonidine Maintenance Prolongs Opioid Abstinence and Decouples Stress From Craving in Daily Life: A Randomized Controlled Trial With Ecological Momentary Assessment.

Authors:  William J Kowalczyk; Karran A Phillips; Michelle L Jobes; Ashley P Kennedy; Udi E Ghitza; Daniel A Agage; John P Schmittner; David H Epstein; Kenzie L Preston
Journal:  Am J Psychiatry       Date:  2015-03-17       Impact factor: 18.112

5.  Context and craving during stressful events in the daily lives of drug-dependent patients.

Authors:  Kenzie L Preston; William J Kowalczyk; Karran A Phillips; Michelle L Jobes; Massoud Vahabzadeh; Jia-Ling Lin; Mustapha Mezghanni; David H Epstein
Journal:  Psychopharmacology (Berl)       Date:  2017-06-08       Impact factor: 4.530

6.  A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.

Authors:  Elmer Yu; Karen Miotto; Evaristo Akerele; Ann Montgomery; Ahmed Elkashef; Robert Walsh; Ivan Montoya; Marian W Fischman; Joseph Collins; Frances McSherry; Kathy Boardman; David K Davies; Charles P O'Brien; Walter Ling; Herbert Kleber; Barbara H Herman
Journal:  Drug Alcohol Depend       Date:  2008-05-27       Impact factor: 4.492

7.  Real-time electronic diary reports of cue exposure and mood in the hours before cocaine and heroin craving and use.

Authors:  David H Epstein; Jessica Willner-Reid; Massoud Vahabzadeh; Mustapha Mezghanni; Jia-Ling Lin; Kenzie L Preston
Journal:  Arch Gen Psychiatry       Date:  2009-01

8.  Retention in methadone and buprenorphine treatment among African Americans.

Authors:  Jan Gryczynski; Shannon Gwin Mitchell; Jerome H Jaffe; Sharon M Kelly; C Patrick Myers; Kevin E O'Grady; Yngvild K Olsen; Robert P Schwartz
Journal:  J Subst Abuse Treat       Date:  2013-04-05

9.  Changes in Quality of Life following Buprenorphine Treatment: Relationship with Treatment Retention and Illicit Opioid Use.

Authors:  Shannon Gwin Mitchell; Jan Gryczynski; Robert P Schwartz; C Patrick Myers; Kevin E O'Grady; Yngvild K Olsen; Jerome H Jaffe
Journal:  J Psychoactive Drugs       Date:  2015 Apr-Jun

Review 10.  Variable selection - A review and recommendations for the practicing statistician.

Authors:  Georg Heinze; Christine Wallisch; Daniela Dunkler
Journal:  Biom J       Date:  2018-01-02       Impact factor: 2.207

View more
  19 in total

1.  Trajectories of craving during medication-assisted treatment for opioid-use disorder: Subtyping for early identification of higher risk.

Authors:  Albert J Burgess-Hull; Leigh V Panlilio; Kenzie L Preston; David H Epstein
Journal:  Drug Alcohol Depend       Date:  2022-02-18       Impact factor: 4.492

2.  Associations between relationship quality and treatment-related stress among couples receiving methadone for opioid use disorder.

Authors:  Courtney A Polenick; Benjamin H Han; Summer N Meyers; Tomorrow D Arnold; Brandi Parker Cotton
Journal:  J Subst Abuse Treat       Date:  2021-07-31

3.  I feel good? Anhedonia might not mean "without pleasure" for people treated for opioid use disorder.

Authors:  Samuel W Stull; Jeremiah W Bertz; Leigh V Panlilio; William J Kowalczyk; Karran A Phillips; Landhing M Moran; Jia-Ling Lin; Massoud Vahabzadeh; Patrick H Finan; Kenzie L Preston; David H Epstein
Journal:  J Abnorm Psychol       Date:  2021-07

4.  Behavioral strategies to reduce stress reactivity in opioid use disorder: Study design.

Authors:  R Kathryn McHugh; Minh D Nguyen; Garrett M Fitzmaurice; Daniel G Dillon
Journal:  Health Psychol       Date:  2020-09       Impact factor: 4.267

5.  The application of digital health to the assessment and treatment of substance use disorders: The past, current, and future role of the National Drug Abuse Treatment Clinical Trials Network.

Authors:  Lisa A Marsch; Aimee Campbell; Cynthia Campbell; Ching-Hua Chen; Emre Ertin; Udi Ghitza; Chantal Lambert-Harris; Saeed Hassanpour; August F Holtyn; Yih-Ing Hser; Petra Jacobs; Jeffrey D Klausner; Shea Lemley; David Kotz; Andrea Meier; Bethany McLeman; Jennifer McNeely; Varun Mishra; Larissa Mooney; Edward Nunes; Chrysovalantis Stafylis; Catherine Stanger; Elizabeth Saunders; Geetha Subramaniam; Sean Young
Journal:  J Subst Abuse Treat       Date:  2020-03

6.  Examining the time-varying association of negative affect and covariates with craving during treatment for prescription opioid dependence with two types of mixed models.

Authors:  Garrett James Jenkins; Michael J Cleveland; Kyler Scott Knapp; Scott C Bunce; H Harrington Cleveland
Journal:  Addict Behav       Date:  2020-09-24       Impact factor: 3.913

Review 7.  A Narrative Literature Review of the Epidemiology, Etiology, and Treatment of Co-Occurring Panic Disorder and Opioid Use Disorder.

Authors:  Ashton E Clark; Shelby R Goodwin; Russell M Marks; Annabelle M Belcher; Emily Heinlein; Melanie E Bennett; Daniel J O Roche
Journal:  J Dual Diagn       Date:  2021-09-28

8.  Using mobile health technologies to test the association of cocaine use with sexual desire and risky sexual behaviors among people with and without HIV who use illicit stimulants.

Authors:  Yunan Xu; Sheri L Towe; Shakiera T Causey; Christina S Meade
Journal:  Drug Alcohol Depend       Date:  2021-05-20       Impact factor: 4.852

9.  Longitudinal patterns of momentary stress during outpatient opioid agonist treatment: A growth-mixture-model approach to classifying patients.

Authors:  Albert J Burgess-Hull; Kirsten E Smith; Destiny Schriefer; Leigh V Panlilio; David H Epstein; Kenzie L Preston
Journal:  Drug Alcohol Depend       Date:  2021-06-25       Impact factor: 4.852

10.  Do out-of-pocket costs influence retention and adherence to medications for opioid use disorder?

Authors:  Christopher Dunphy; Cora Peterson; Kun Zhang; Christopher M Jones
Journal:  Drug Alcohol Depend       Date:  2021-05-21       Impact factor: 4.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.